分析Thopaz数字化胸腔引流系统用于肺结核术后持续性漏气的临床应用价值，为临床优化引流管理方案提供参考。

回顾性纳入2023年1月~2025年12月在本院接受肺结核手术并出现术后持续性漏气的患者共68例，按照引流方式不同分为观察组与对照组，每组各34例。按照引流方式分为观察组与对照组，每组各34例。2组患者在年龄、性别、肺结核病变范围、手术方式、术前肺功能等一般资料方面比较，差异均无统计学意义（P＞0.05），具有可比性。观察组采用Thopaz数字化胸腔引流系统实施引流，对照组采用传统胸腔闭式水封瓶引流。对比2组漏气持续时长、胸管留置时间、住院天数、治疗有效率、术后并发症（肺部感染、皮下气肿、纵隔气肿）发生情况，同时比较治疗前后疼痛VAS评分、胸腔引流液量变化及患者满意度。

观察组漏气持续时间（5.2±1.8）d、胸管留置时间（6.5±2.1）d、住院时间（12.3±3.2）d，均明显短于对照组的（8.7±2.5）d、（10.3±2.7）d、（17.8±4.1）d，差异均有统计学意义（P＜0.05）。观察组治疗有效率为94.12%（32/34），高于对照组 73.53%（25/34），差异有统计学意义（P＜0.05）。观察组肺部感染、皮下气肿、纵隔气肿发生率分别为 5.88%、8.82%、2.94%，均低于对照组 23.53%、26.47%、14.71%，差异均有统计学意义（P＜0.05）。治疗3 d后，观察组VAS评分为（2.8±1.1）分，显著低于对照组（4.9±1.5）分（P＜0.05）；术后3 d、7 d观察组引流液量均少于对照组（P＜0.05）。观察组患者满意度97.06%，显著高于对照组79.41%（P＜0.05）。

Thopaz数字化胸腔引流系统可安全、有效地管理肺结核术后持续性漏气，能显著缩短漏气时间、带管时间及住院时间，提高治疗成功率，降低并发症，并改善患者体验，具有临床推广价值。

To evaluate the clinical efficacy of the Thopaz digital chest drainage system in managing persistent air leak following pulmonary tuberculosis surgery, in order to provide evidence to support clinical decision-making.

A retrospective analysis was performed on 68 patients who developed persistent air leak following pulmonary tuberculosis surgery between January 2023 and December 2025. Patients were divided into an observation group (n=34) and a control group (n=34) according to the drainage method used. The two groups were comparable in terms of age, gender, lesion scope, surgical approach, and preoperative pulmonary function (P＞0.05). The observation group was managed with the Thopaz digital chest drainage system, while the control group received conventional closed chest drainage. The duration of air leak, chest tube indwelling time, length of hospital stay, treatment effective rate, postoperative complications, VAS pain score, drainage volume, and patient satisfaction were compared between the two groups.

The duration of air leak, chest tube indwelling time, and hospital stay in the observation group were significantly shorter than those in the control group (P＜0.05). The effective rate in the observation group was 94.12%, which was significantly higher than the 73.53% observed in the control group (P＜0.05). The incidences of pulmonary infection, subcutaneous emphysema, and mediastinal emphysema in the observation group were 5.88%, 8.82%, and 2.94%, respectively, all lower than those in the control group (P＜0.05). At 3 days after treatment, the VAS score in the observation group was significantly lower, as was the drainage volume at both 3 and 7 days (P＜0.05). Patient satisfaction n the observation group was 97.06%, higher than the 79.41% in the control group (P＜0.05).

The Thopaz digital chest drainage system is safe and effective in managing persistent air leak after pulmonary tuberculosis surgery. It significantly shortens air leak duration, chest tube indwelling time, and hospital stay, improves treatment success rate, reduces complications, and enhances patient experience. Therefore, it is worthy of clinical promotion.